4th Dec 2007 12:24
BTG PLC04 December 2007 BTG plc Appoints Dr John Brown as Chairman Designate London, UK, 4 December 2007: BTG plc (LSE: BGC), the life sciences company,today announces the following Board changes. Dr John Brown is to join the Board of BTG on 1 January 2008 as a non-executivedirector and, upon the retirement of Sir Brian Fender on 3 March 2008, willbecome non-executive Chairman of BTG. Sir Brian Fender commented: "I am delighted that John Brown will join our board and will succeed me asChairman of BTG. I have enjoyed the years I have spent as a director and thenChairman of this exciting company and wish John every success in moving BTGforward in the coming years." John Brown, PhD MBA FRSE is a non-executive director of a number of public andprivate biotech companies including Ardana plc, Protherics plc and Vectura Groupplc, and was a director of Cambridge Antibody Technology plc until its recentacquisition by AstraZeneca. He currently chairs the Governing Council of theRoslin Institute in Edinburgh and is chairman of Scottish Biomedical, CXR Ltdand SingVax Pte Ltd. He sits on the advisory board of the Life Sciences ITI inScotland, is a member of the UK Technology Strategy Board and an advisor toseveral private equity and venture capital funds. Until late 2003, Dr Brown was Chief Executive of Acambis plc, a leading producerof vaccines to treat and prevent infectious disease. John holds a PhD inneuropharmacology from Edinburgh University and is a Fellow of the Royal Societyof Edinburgh. There are no further details to be disclosed in relation to paragraph 9.6.13R ofthe Financial Services Authority Listing Rules. Ends For further information contact: BTG Financial DynamicsAndy Burrows, Director of Investor Relations Ben Atwell +44 (0)20 7575 1741; mobile: +44 (0)7990 530605 +44 (0)20 7831 3113 Christine Soden, Chief Financial Officer +44 (0)20 7575 1591 About BTG BTG in-licenses, develops and commercialises pharmaceuticals principally in theareas of neuroscience and oncology. The company has a substantial and growingrevenue stream of royalties from out-licensed products and a broad, expandinginternal pipeline of development programmes. BTG operates from offices inLondon, Philadelphia and Osaka. For further information, visit: www.btgplc.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
BTG